STOCK TITAN
  1. Home
  2. News
  3. CRSP

CRISPR Therapeutics AG - CRSP STOCK NEWS

Welcome to our dedicated page for CRISPR Therapeutics news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics stock.

CRISPR Therapeutics AG (symbol: CRSP) is a pioneering gene editing company dedicated to the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary technology allows for precise, directed changes to genomic DNA, enabling the treatment of genetically defined diseases.

The company's portfolio spans a broad range of therapeutic programs, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. One of its notable achievements is the development and approval of Casgevy, a therapeutic targeting sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals.

To bolster its research and development, CRISPR Therapeutics has forged strategic partnerships with renowned companies such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. These collaborations aim to accelerate and expand the company's efforts in bringing novel therapies to market.

Headquartered in Zug, Switzerland, CRISPR Therapeutics operates through its wholly-owned U.S. subsidiary, with R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California, and London, United Kingdom.

The company's ongoing projects include advancing gene editing programs in immuno-oncology and developing stem cell-derived therapies for the treatment of Type 1 diabetes. With its innovative approach and strategic collaborations, CRISPR Therapeutics is at the forefront of the gene editing revolution, poised to make significant impacts in the field of medicine.

For more information, please visit www.crisprtx.com.

News

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) announced the FDA approval of CASGEVY™, a CRISPR-based gene-editing therapy, for the treatment of sickle cell disease in patients 12 years and older. This marks the first-ever approval of a CRISPR-based gene-editing therapy in the U.S. and offers a one-time treatment option for approximately 16,000 eligible patients with severe sickle cell disease. The therapy has the potential to eliminate severe vaso-occlusive crises and hospitalizations caused by the disease, providing a functional cure for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
fda approval
-
News

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) provided an update on its immuno-oncology pipeline, focusing on next-generation CAR T product candidates CTX112™ targeting CD19 and CTX131™ targeting CD70. Preliminary data from ongoing clinical trials suggest that these candidates may improve upon the clinical profile of first-generation candidates CTX110 and CTX130, with increased CAR T cell expansion and functional persistence. The Company is transitioning patients treated with CTX110 and CTX130 to long-term follow-up and plans to expand trials of CTX112 into autoimmune disease and CTX131 into hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
News

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced the first regulatory authorization of a CRISPR-based gene-editing therapy in the world. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy is indicated for eligible patients 12 years of age and older. CASGEVY has been authorized for the treatment of patients with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. The safety profile of patients treated with CASGEVY in clinical trials is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
News

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
CRISPR Therapeutics completes Advisory Committee meeting for exa-cel for severe sickle cell disease (SCD) and assigns Prescription Drug User Fee Act (PDUFA) target action dates for SCD and transfusion-dependent beta thalassemia (TDT). Ongoing clinical trials for CAR T product candidates targeting B-cell malignancies, T cell malignancies and solid tumors. Also, clinical trials ongoing for VCTX211 for Type 1 Diabetes and CTX310 targeting angiopoietin-related protein 3 (ANGPTL3).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.57%
Tags
earnings
-
News

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

Rhea-AI Summary
CRISPR Therapeutics announces preclinical data from investigational programs for cardiovascular disease treatment. CTX310™ shows durable reductions in ANGPTL3 protein and triglyceride levels in non-human primates after a single dose. CTX320™ shows durable reductions in lipoprotein(a) levels in non-human primates after a single dose. Clinical trial initiated for CTX310™, targeting ANGPTL3. CTX320™ targeting Lp(a) is on track to enter the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
clinical trial
-
News

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

Rhea-AI Summary
CRISPR Therapeutics announced the completion of the FDA's advisory committee meeting for exa-cel, a potential therapy for severe sickle cell disease (SCD). The PDUFA target action date for SCD is December 8, 2023. If approved, exa-cel could be the first genetic therapy available to approximately 20,000 people with severe SCD in the U.S. The BLA for transfusion-dependent beta-thalassemia (TDT) has a PDUFA date of March 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.38%
Tags
none
News

CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)

Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) announces trading halt as FDA reviews Biologics License Application for exagamglogene autotemcel (exa-cel) for sickle cell disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Rhea-AI Summary
CRISPR Therapeutics announces poster presentations of preclinical data at SITC 38th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
-
News

CRISPR Therapeutics Announces Leadership Transition

Rhea-AI Summary
CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
management
News

CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

Rhea-AI Summary
CRISPR Therapeutics to participate in fireside chat at Citi's Biopharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences

FAQ

What is the current stock price of CRISPR Therapeutics (CRSP)?

The current stock price of CRISPR Therapeutics (CRSP) is $46.29 as of November 21, 2024.

What is the market cap of CRISPR Therapeutics (CRSP)?

The market cap of CRISPR Therapeutics (CRSP) is approximately 4.0B.

What is CRISPR Therapeutics AG?

CRISPR Therapeutics AG is a gene editing company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform.

What does the CRISPR/Cas9 platform do?

CRISPR/Cas9 is a revolutionary gene editing technology that enables precise, directed changes to genomic DNA, allowing for the treatment of genetically defined diseases.

Where is CRISPR Therapeutics headquartered?

CRISPR Therapeutics is headquartered in Zug, Switzerland, with additional offices in the U.S. and the UK.

What is Casgevy?

Casgevy is a therapeutic developed by CRISPR Therapeutics in collaboration with Vertex Pharmaceuticals, targeting sickle cell disease and transfusion-dependent beta-thalassemia.

What types of diseases is CRISPR Therapeutics targeting?

CRISPR Therapeutics is targeting a range of diseases including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

Who are CRISPR Therapeutics' key partners?

CRISPR Therapeutics has established strategic collaborations with companies like Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc.

What are some of CRISPR Therapeutics' current projects?

Current projects include advancing gene editing programs for immuno-oncology and developing stem cell-derived therapies for Type 1 diabetes.

Where are CRISPR Therapeutics' R&D operations based?

The company's R&D operations are based in Cambridge, Massachusetts.

How has CRISPR Therapeutics impacted the field of medicine?

CRISPR Therapeutics is at the forefront of the gene editing revolution, developing innovative therapies for serious diseases and collaborating with leading companies.

Where can I find more information about CRISPR Therapeutics?

More information about CRISPR Therapeutics can be found on their website at www.crisprtx.com.

Stock CRSP logo
CRISPR Therapeutics AG

Nasdaq:CRSP

CRSP Rankings

#1445 Ranked by Market Cap
N/A Ranked by Dividends

CRSP Stock Data

4.03B
83.89M
1.71%
72.21%
21.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ZUG